110 related articles for article (PubMed ID: 1949848)
1. [Status of recombinant cytokines in treatment of leukemic diseases].
Geissler K
Wien Med Wochenschr; 1991; 141(9-10):217-20. PubMed ID: 1949848
[TBL] [Abstract][Full Text] [Related]
2. Biological molecules in the treatment of hematological disorders.
Kurzrock R; Talpaz M; Gutterman U
Sangre (Barc); 1989 Feb; 34(1):53-8. PubMed ID: 2469130
[No Abstract] [Full Text] [Related]
3. [Leukemias in advanced age. Part 2: Myelodysplastic syndrome and chronic leukemia].
Jehn U
Fortschr Med; 1994 May; 112(13):180-4. PubMed ID: 8020858
[TBL] [Abstract][Full Text] [Related]
4. Leukemias and myeloma.
Wiernik PH
Cancer Chemother Biol Response Modif; 1990; 11():321-42. PubMed ID: 2223398
[No Abstract] [Full Text] [Related]
5. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture.
Engelhardt M; Mackenzie K; Drullinsky P; Silver RT; Moore MA
Cancer Res; 2000 Feb; 60(3):610-7. PubMed ID: 10676644
[TBL] [Abstract][Full Text] [Related]
6. [Use of interferon in patients with hairy cell leukemia and myeloproliferative disorders].
Skotnicki AB; Wolska-Smoleń T
Acta Haematol Pol; 1994; 25(2 Suppl 1):124-35. PubMed ID: 8067197
[TBL] [Abstract][Full Text] [Related]
7. Leukemias and plasma cell myeloma.
Wiernik PH
Cancer Chemother Biol Response Modif; 1992; 13():327-48. PubMed ID: 1389914
[No Abstract] [Full Text] [Related]
8. Leukemias and myeloma.
Wiernik PH
Cancer Chemother Biol Response Modif; 1991; 12():327-46. PubMed ID: 1931449
[No Abstract] [Full Text] [Related]
9. Interferon-alpha and interleukin-2 as treatment for leukemia relapse after allogeneic bone marrow transplantation.
Giralt S; O'Brien S; Talpaz M; Van Besien K; Chan KW; Rondón G; Andersson B; Mehra R; Khouri I; Estey E
Cytokines Mol Ther; 1995 Jun; 1(2):115-22. PubMed ID: 9384668
[TBL] [Abstract][Full Text] [Related]
10. Use of interferon in the treatment of chronic myelogenous leukemia.
Talpaz M
Semin Oncol; 1994 Dec; 21(6 Suppl 14):3-7. PubMed ID: 7992097
[TBL] [Abstract][Full Text] [Related]
11. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies.
Zheng Z; Takahashi M; Aoki S; Toba K; Liu A; Osman Y; Takahashi H; Tsukada N; Suzuki N; Nikkuni K; Furukawa T; Koike T; Aizawa Y
J Exp Clin Cancer Res; 1998 Sep; 17(3):251-8. PubMed ID: 9894758
[TBL] [Abstract][Full Text] [Related]
12. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
[TBL] [Abstract][Full Text] [Related]
13. [Interferon-alpha in the treatment of hematologic neoplasms].
Aulitzky W; Gastl G; Tilg H; Troppmair J; Leiter E; Geissler D; Flener R; Huber C
Wien Med Wochenschr; 1986 Apr; 136(7-8):172-81. PubMed ID: 3524022
[TBL] [Abstract][Full Text] [Related]
14. Cytokines in the treatment of hematological disorders: recent progress and perspectives.
Robak T
Arch Immunol Ther Exp (Warsz); 1996; 44(1):5-9. PubMed ID: 8874763
[TBL] [Abstract][Full Text] [Related]
15. Myelodysplastic syndromes: the pediatric point of view.
Locatelli F; Zecca M; Pession A; Maserati E; De Stefano P; Severi F
Haematologica; 1995; 80(3):268-79. PubMed ID: 7672722
[TBL] [Abstract][Full Text] [Related]
16. Cytokine therapy for hematological malignancies.
Ezaki K; Tsuzuki M
Gan To Kagaku Ryoho; 1997 May; 24 Suppl 1():182-94. PubMed ID: 9210900
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
Saito T; Kanda Y; Kami M; Kato K; Shoji N; Kanai S; Ohnishi T; Kawano Y; Nakai K; Ogasawara T; Matsubara H; Makimoto A; Tanosaki R; Tobinai K; Wakasugi H; Takaue Y; Mineishi S
Clin Cancer Res; 2002 Apr; 8(4):1014-20. PubMed ID: 11948108
[TBL] [Abstract][Full Text] [Related]
18. Differentiation-inducing effect of recombinant human tumor necrosis factor alpha and gamma-interferon in vitro on blast cells from patients with acute myeloid leukemia and myeloid blast crisis of chronic myeloid leukemia.
Geissler K; Tricot G; Leemhuis T; Walker E; Broxmeyer HE
Cancer Res; 1989 Jun; 49(11):3057-62. PubMed ID: 2497971
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
Ries C; Loher F; Zang C; Ismair MG; Petrides PE
Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
[TBL] [Abstract][Full Text] [Related]
20. Leukemia inhibitory factor in long-term adherent layer cultures: increased levels of bioactive protein in leukemia and modulation by IL-4, IL-1 beta, and TNF-alpha.
Wetzler M; Estrov Z; Talpaz M; Kim KJ; Alphonso M; Srinivasan R; Kurzrock R
Cancer Res; 1994 Apr; 54(7):1837-42. PubMed ID: 8137298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
